secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001628280-25-025329
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics Q1 net loss narrows to $38.6M; ZYNLONTA revenue $17.4M, LOTIS-7 shows 95.5% ORR
--------------------------------------------------------------------------------

- Q1 product revenue $17.4M vs $17.8M YoY; license revenue $5.6M including $5M Canadian milestone.
- Net loss $38.6M ($0.36/sh) vs $46.6M ($0.56); adjusted net loss $24.0M ($0.22).
- Cash $194.7M at March 31; runway expected into H2 2026.
- LOTIS-7 (ZYNLONTA+glofitamab) enrolled 40 patients; abstract shows 95.5% ORR, 90.9% CR.
- LOTIS-5 confirmatory trial on track for PFS events by end of 2025; ADCT-602 discontinued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000162828025025329/0001628280-25-025329-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000162828025025329/adc-20250514.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-025329

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer